Epion Therapeutics</a> (Copy)
2 known investors
Epion Therapeutics is developing EpiSmart, a minimally-invasive corneal cross-linking system to treat keratoconus and corneal ectasia without disrupting the epithelium. The treatment targets patients with ectatic corneal disease as an early-intervention standard of care.
Investors · 2
Frequently asked questions
- What does Epion Therapeutics</a> (Copy) do?
- Epion Therapeutics is developing EpiSmart, a minimally-invasive corneal cross-linking system to treat keratoconus and corneal ectasia without disrupting the epithelium. The treatment targets patients with ectatic corneal disease as an early-intervention standard of care.
- Who are Epion Therapeutics</a> (Copy)'s investors?
- Epion Therapeutics</a> (Copy)'s investors include 7G BioVentures, New World Angels.